Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors.

“We have assembled a distinguished and diverse group of scientific oncology experts from leading research institutions and industry groups worldwide to guide Qualigen Therapeutics through a rigorous and expeditious path to develop QN-302 for pancreatic cancer, and possibly other important indications. The formation of this SAB demonstrates our strong belief in the potential of QN-302, and we are confident that the vast experience of its members will help advance the program,” commented Michael Poirier, Qualigen’s Chairman and CEO.

Read the full article at Biospace.com